Prelude Therapeutics Net Worth
Prelude Therapeutics Net Worth Breakdown | PRLD |
Prelude Therapeutics Net Worth Analysis
Prelude Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Prelude Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Prelude Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Prelude Therapeutics' net worth analysis. One common approach is to calculate Prelude Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Prelude Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Prelude Therapeutics' net worth. This approach calculates the present value of Prelude Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Prelude Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Prelude Therapeutics' net worth. This involves comparing Prelude Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Prelude Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Prelude Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Prelude Therapeutics' net worth research are outlined below:
| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics has some characteristics of a very speculative penny stock | |
| Prelude Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (121.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (107.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Prelude Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Down -39.13 percent in 4 Weeks, Heres Why You Should You Buy the Dip in Prelude Therapeutics - MSN |
Prelude Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Prelude Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Prelude Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Prelude Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Prelude Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Prelude Therapeutics backward and forwards among themselves. Prelude Therapeutics' institutional investor refers to the entity that pools money to purchase Prelude Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 391.7 K | T. Rowe Price Investment Management,inc. | 2024-09-30 | 281.6 K | State Street Corp | 2024-06-30 | 211.7 K | Renaissance Technologies Corp | 2024-09-30 | 196.9 K | Bridgeway Capital Management, Llc | 2024-09-30 | 176.1 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 175 K | Td Asset Management Inc | 2024-09-30 | 160.7 K | Charles Schwab Investment Management Inc | 2024-09-30 | 133.2 K | Northern Trust Corp | 2024-09-30 | 106.4 K | Orbimed Advisors, Llc | 2024-06-30 | 10.9 M | Baker Bros Advisors Lp | 2024-09-30 | 10.1 M |
Follow Prelude Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.06 M.Market Cap |
|
Project Prelude Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.52) | (0.54) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.51) | (0.49) |
When accessing Prelude Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Prelude Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Prelude Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Prelude Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prelude Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prelude Therapeutics' management manipulating its earnings.
Evaluate Prelude Therapeutics' management efficiency
Prelude Therapeutics has return on total asset (ROA) of (0.3929) % which means that it has lost $0.3929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6664) %, meaning that it created substantial loss on money invested by shareholders. Prelude Therapeutics' management efficiency ratios could be used to measure how well Prelude Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.54. At present, Prelude Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 11.4 M, whereas Net Tangible Assets are forecasted to decline to about 136.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.93 | 2.22 | |
| Tangible Book Value Per Share | 3.93 | 2.22 | |
| Enterprise Value Over EBITDA | (1.90) | (2.00) | |
| Price Book Value Ratio | 1.09 | 1.14 | |
| Enterprise Value Multiple | (1.90) | (2.00) | |
| Price Fair Value | 1.09 | 1.14 | |
| Enterprise Value | 249.3 M | 236.9 M |
The decision-making processes within Prelude Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Revenue 3 M | Revenue Per Share 0.04 | Return On Equity (0.67) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prelude Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prelude Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prelude Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prelude Therapeutics time-series forecasting models is one of many Prelude Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Prelude Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Prelude Therapeutics Earnings per Share Projection vs Actual
Prelude Therapeutics Corporate Management
| Laurent MBA | Chief Officer | Profile | |
| William MD | Senior Development | Profile | |
| Naveen Babbar | Senior Medicine | Profile | |
| Neelesh MD | VP Devel | Profile | |
| Aimee Crombie | Senior Operations | Profile | |
| Madhu Pudipeddi | Senior Operations | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share 0.04 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.